Members Login
 

The WHO Early Release Guideline on ARV and PrEP

were published on September

30th, 2015 and can be

found here:

 Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV

JIAS Special Issue: PrEP Implementation Science: State-of-the-Art and Research Agenda, organized by NEMUS (published July 2015).

 Please visit Nemus´Youtube channell

 

Follow us in Facebook

 

and Twiter

NEMUS Activities 2016

Special NEMUS Global Webinar Program for World AIDS Day #26 "ARV-based prevention and PrEP research - News from the 2016 Research for Prevention Conference" Featured

Rate this item
(0 votes)

Dear colleague:

 

On occasion of World AIDS Day 2016, NEMUS is pleased to offer a Special Program of 3 presentation of its Global Webinar Series: the second on Monday 28 November, Raphael Landovitz, MD, who was one of the Lead Rapporteurs at the recent R4P Conference, will present on 

 

ARV-based prevention and PrEP research - News from the 2016 Research for Prevention Conference
(28 November)

Rafael Landovitz

Raphael J Landovitz´s clinical research career focuses on optimizing the use of HIV antiretroviral therapy for both HIV treatment and HIV prevention.
Dr. Landovitz was trained at Princeton University and Harvard Medical School. He completed post-graduate training in internal medicine at Brigham and Women’s Hospital (1996-1999) and Infectious Diseases and HIV Medicine at Brigham and Women’s Hospital and Massachusetts General Hospital (1999-2001). The served as Chief Medical Resident at the Brigham and Women’s Hospital from 2001-2002. He served on the faculty of the Division of Infectious Diseases at the Brigham and Women’s Hospital from 2001-2005, and then as Medical Co-Director of the Vietnam CDC-Harvard Medical School AIDS Partnership. He is Currently Associate Professor of Medicine in the Division of Infectious Diseases at UCLA, Associate Director of the UCLA Center for Clinical AIDS Research & Education, and Co-Director of the UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). He is leading the NIH/DAIDS funded Phase 2a and Phase 3 studies of long-acting injectable PrEP using cabotegravir (GSK 1265744). He was awarded the John Carey Young Investigator Award by the AIDS Clinical Trials Group in 2010..

 

 

Share this

Submit to DeliciousSubmit to DiggSubmit to FacebookSubmit to Google PlusSubmit to StumbleuponSubmit to TechnoratiSubmit to TwitterSubmit to LinkedIn
Read 161 times Last modified on Friday, 02 December 2016 21:09

Media